Secretion of soluble VEGF receptor 2 by microvascular endothelial cells derived by human benign prostatic hyperplasia

References

• Agostini H, Boden K, Unsold A, Martin G, Hansen L, Fiedler U, Esser N, Marme D. A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. Curr Eye Res 2005; 30: 249–257
   PubMed Web of Science ®Google Scholar
• Bates M, Kovalenko B, Wilson L, Moscatelli D. Endothelial cells support the growth of prostate tissue in vivo. Prostate 2008; 68: 893–901
   PubMedGoogle Scholar
• Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor. Int J Cancer 1999; 80: 868–874
   PubMed Web of Science ®Google Scholar
• Cebe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnership. Cell Mol Life Sci 2006; 63: 601–615
   PubMed Web of Science ®Google Scholar
• Dall'Era MA, Shih SJ, Yang J, Benik S, Gandour-Edwards R, Evans CP. Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer. Prostate Cancer Prostatic Dis 2001; 4: 106–111
   PubMedGoogle Scholar
• Ebos JML, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004; 2: 315–326
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Bogdanovic E, Alami J, Van slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008; 68: 521–529
   PubMed Web of Science ®Google Scholar
• Folkman J. Editorial: Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 1998; 139: 441–442
   PubMed Web of Science ®Google Scholar
• Franck-Lissbrandt I, Häggström S, Damber J-E, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451–456
   PubMedGoogle Scholar
• Gerritsen ME. Functional heterogeneity of vascular endothelial cells. Biochem Pharmacol 1987; 36: 2701–2711
   PubMed Web of Science ®Google Scholar
• Gimbrone MA, Jr., Cotran RS, Folkman J. Human vascular endothelial cells in culture. J Cell Biol 1974; 60: 673–684
   PubMed Web of Science ®Google Scholar
• Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, Gustin JA, Baerwald MR, Jaffe EA, Warren RS, Donner DB. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 2000; 275: 11216–11221
   PubMed Web of Science ®Google Scholar
• Häggström S, Bergh A, Damber J-E. Vascular endothelial growth factor content in metastasizing and nonmetastasizing dunning prostatic adenocarcinoma. Prostate 2000; 45: 42–50
   PubMedGoogle Scholar
• Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. Expresssion of the VEGF-receptor flt-1 in benign, premalignant and malignant prostate tissues. J Urol 2000; 164: 506–510
   PubMed Web of Science ®Google Scholar
• Hrouda D, Nicol DL, Gardiner RA. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol Res 2003; 30: 347–355
   PubMedGoogle Scholar
• Janßen M, Albrecht M, Möschler O, Renneberg H, Fritz B, Aumüller G, Konrad L. Cell lineage characteristics of human prostatic stromal cells cultured in vitro. Prostate 2000; 43: 20–30
   PubMedGoogle Scholar
• Joseph IB, Isaacs JT. Macrophage role in the anti-prostate cancer response to one class of angiogenic agents. J Natl Cancer Inst 1998; 90: 1648–1653
   PubMed Web of Science ®Google Scholar
• Kappas NC, Zeng G, Chappell JC, Kearney JB, Hazarika S, Kallianos KG, Patterson C, Annex BH, Bautch VL. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 2008; 181: 847–858
   PubMed Web of Science ®Google Scholar
• Krupski T, Harding MA, Herce ME, Gulding KM, Stoler MH, Theodorescu D. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors 2001; 18: 287–302
   PubMed Web of Science ®Google Scholar
• Latil A, Bieche I, Pesche S, Valeri A, Fournier G, Cussenot O, Lidereau R. VEGF overexpression in clinically localized prostate tumors and neuropillin-1 overexpression in metastatic forms. Int J Cancer 2000; 89: 167–171
   PubMed Web of Science ®Google Scholar
• Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001; 35: 437–452
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Nakagami H, Cui TX, Iwai M, Shiuchi T, Takeda-Matsubara Y, Wu L, Horiuchi M. Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 238–242
   PubMedGoogle Scholar
• Nakajima Y, DelliPizzi A, Mallouh C, Ferreri NR. Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines. Urol Res 1995; 23: 205–210
   PubMedGoogle Scholar
• Pieh C, Agostini H, Buschbeck C, Kruger M, Schulte-Monting J, Zirrgiebel U, Drevs J, Lagreze WA. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: Relationship to retinopathy of prematurity. Br J Ophthalmol 2008; 92: 689–693
   PubMed Web of Science ®Google Scholar
• Polnaszek N, Kwabi-Addo B, Wang J, Ittmann M. Fgf17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia. Prostate 2004; 60: 18–24
   PubMed Web of Science ®Google Scholar
• Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther 2005; 4: 315–321
   PubMedGoogle Scholar
• Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 1998; 241: 161–170
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor receptor-2: Its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003; 94: 751–756
   PubMed Web of Science ®Google Scholar
• Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006a; 39: 469–478
   PubMedGoogle Scholar
• Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor2: Its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006b; 13: 63–69
   PubMed Web of Science ®Google Scholar
• Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 1998; 251: 287–290
   PubMed Web of Science ®Google Scholar
• Stachon A, Schlüter T, Köller M, Weisser H, Krieg M. Primary culture of microvascular endothelial cells from human benign prostatic hyperplasia. Prostate 2001; 48: 156–164
   PubMedGoogle Scholar
• Stachon A, Schlüter T, Junker K, Knopf HJ, Neuser RD, Krieg M. The secretion of endothelin-1 by microvascular endothelial cells from human benign prostatic hyperplasia is inhibited by vascular endothelial growth factor. Growth Factors 2004; 22: 281–289
   PubMed Web of Science ®Google Scholar
• Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410–422
   PubMed Web of Science ®Google Scholar
• Szentirmai O, Baker CH, Bullain SS, Lin N, Takahashi M, Folkman J, Mulligan RC, Carter BS. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: Laboratory investigation. J Neurosurg 2008; 108: 979–988
   PubMed Web of Science ®Google Scholar
• Thorin E, Shatos MA, Shreeve SM, Walters CL, Bevan JA. Human vascular endothelium heterogeneity. A comparative study of cerebral and peripheral cultured vascular endothelial cells. Stroke 1997; 28: 375–381
   PubMed Web of Science ®Google Scholar
• van Moorselaar RJ, van Stratum P, Borm G, Debruyne FM, Schalken JA. Differential antiproliferative activities of alpha- and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. Prostate 1991; 18: 331–344
   PubMedGoogle Scholar
• Vogel C, Bauer A, Wiesnet M, Preissner KT, Schaper W, Marti HH, Fischer S. Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway. J Cell Physiol 2007; 212: 236–243
   PubMedGoogle Scholar
• Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbanska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 2003; 14: 149–153
   PubMed Web of Science ®Google Scholar
• Zhao X, van Steenbrugge GJ, Schroder FH. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor. Urol Res 1992; 20: 193–197
   PubMedGoogle Scholar